WallStreetZenWallStreetZen

NASDAQ: IMUX
Immunic Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for IMUX

Based on 5 analysts offering 12 month price targets for Immunic Inc

Min Forecast
$22.00+85.81%
Avg Forecast
$37.80+219.26%
Max Forecast
$70.00+491.22%

Should I buy or sell IMUX stock?

Based on 6 analysts offering ratings for Immunic Inc.

Strong Buy
Strong Buy
3 analysts 50%
Buy
2 analysts 33.33%
Hold
1 analysts 16.67%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although IMUX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates IMUX as a "Hold". Stocks with a Zen Rating of Hold have had an average return of +5.11% per year. Learn More

Be the first to know when Wall Street analysts revise their IMUX stock forecasts and price targets.

IMUX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-09-10
lockedlocked$00.00+00.00%2026-09-10
lockedlocked$00.00+00.00%2026-05-22
lockedlocked$00.00+00.00%2026-04-17
lockedlocked$00.00+00.00%2026-04-15
Guggenheim
Top 2%
99
Strong BuyInitiates Coverage On$70.00+491.22%2026-03-24

1 of 1

Forecast return on equity

Is IMUX forecast to generate an efficient return?

Company
-6.89%
Industry
18.97%
Market
168.91%
IMUX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is IMUX forecast to generate an efficient return on assets?

Company
-5.53%
Industry
23.61%
IMUX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

IMUX earnings per share forecast

What is IMUX's earnings per share in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
-$3.67
Avg 2 year Forecast
-$2.44
Avg 3 year Forecast
-$2.52

IMUX revenue forecast

What is IMUX's revenue in the next 3 years based on estimates from 13 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$11.3M
Avg 3 year Forecast
$76.5M

IMUX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
IMUX$11.84$37.80+219.26%Strong Buy
QSI$0.74N/AN/A
OTLK$0.66$5.20+686.69%Buy
MOLN$4.18$13.00+211.00%Buy
CRBP$8.24$37.50+355.10%Strong Buy
View Top Biotech Stocks

Immunic Stock Forecast FAQ

Is Immunic Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: IMUX) stock is to Strong Buy IMUX stock.

Out of 6 analysts, 3 (50%) are recommending IMUX as a Strong Buy, 2 (33.33%) are recommending IMUX as a Buy, 1 (16.67%) are recommending IMUX as a Hold, 0 (0%) are recommending IMUX as a Sell, and 0 (0%) are recommending IMUX as a Strong Sell.

If you're new to stock investing, here's how to buy Immunic stock.

What is IMUX's earnings growth forecast for 2026-2028?

(NASDAQ: IMUX) Immunic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.27%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 30.89%.

Immunic's earnings in 2026 is -$111,566,000.On average, 13 Wall Street analysts forecast IMUX's earnings for 2026 to be -$50,011,065, with the lowest IMUX earnings forecast at -$76,538,638, and the highest IMUX earnings forecast at -$44,269,473. On average, 12 Wall Street analysts forecast IMUX's earnings for 2027 to be -$33,321,153, with the lowest IMUX earnings forecast at -$62,606,272, and the highest IMUX earnings forecast at -$10,028,683.

In 2028, IMUX is forecast to generate -$34,324,021 in earnings, with the lowest earnings forecast at -$61,776,689 and the highest earnings forecast at -$20,773,701.

What is IMUX's revenue growth forecast for 2026-2028?

(NASDAQ: IMUX) Immunic's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.86%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.25%.

Immunic's revenue in 2026 is $0.On average, 13 Wall Street analysts forecast IMUX's revenue for 2026 to be $0, with the lowest IMUX revenue forecast at $0, and the highest IMUX revenue forecast at $0. On average, 12 Wall Street analysts forecast IMUX's revenue for 2027 to be $154,632,745, with the lowest IMUX revenue forecast at $0, and the highest IMUX revenue forecast at $1,432,669,035.

In 2028, IMUX is forecast to generate $1,044,402,082 in revenue, with the lowest revenue forecast at $190,585,915 and the highest revenue forecast at $2,289,405,118.

What is IMUX's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: IMUX) forecast ROA is -5.53%, which is lower than the forecast US Biotechnology industry average of 23.61%.

What is IMUX's Price Target?

According to 5 Wall Street analysts that have issued a 1 year IMUX price target, the average IMUX price target is $37.80, with the highest IMUX stock price forecast at $70.00 and the lowest IMUX stock price forecast at $22.00.

On average, Wall Street analysts predict that Immunic's share price could reach $37.80 by Sep 10, 2027. The average Immunic stock price prediction forecasts a potential upside of 219.26% from the current IMUX share price of $11.84.

What is IMUX's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: IMUX) Immunic's current Earnings Per Share (EPS) is -$3.88. On average, analysts forecast that IMUX's EPS will be -$3.67 for 2026, with the lowest EPS forecast at -$5.61, and the highest EPS forecast at -$3.24. On average, analysts forecast that IMUX's EPS will be -$2.44 for 2027, with the lowest EPS forecast at -$4.59, and the highest EPS forecast at -$0.74. In 2028, IMUX's EPS is forecast to hit -$2.52 (min: -$4.53, max: -$1.52).

What is IMUX's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: IMUX) forecast ROE is -6.89%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.